Aptamers as inhibitors of target proteins

Expert Opinion on Therapeutic Patents

Volumn 19, Issue 8, 2009, Pages 1073-1082

  Missailidis, S ^a   Hardy, A ^a  

^a OPEN UNIVERSITY   (United Kingdom)

Author keywords

Aptamers; Patents; SELEX; Therapeutics

Indexed keywords

AGRO 100; ANGIOGENESIS INHIBITOR; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; APTA 02; APTAMER; ARC 127; ARC 1779; ARC 183; ARC 187; ARC 1905; AS 1411; DOCETAXEL; FLUOROURACIL; GS 522; IMATINIB; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR; MUCIN 1; NOX A 12; NOX A 50; NOX A12; NOX A50; NU 172; PACLITAXEL; PEGAPTANIB; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; REG 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; XANTOS 3;

ACUTE CORONARY SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; BACILLUS ANTHRACIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLON CARCINOMA; DIABETIC RETINOPATHY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MARKETING; DRUG PROTEIN BINDING; DRUG SAFETY; ENTEROCOCCUS; GRAFT REJECTION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFLAMMATION; INFLUENZA VIRUS; MULTIPLE SCLEROSIS; NEOPLASM; NONHUMAN; PATENT; PROTEIN TARGETING; PROTEOMICS; RETINA MACULA AGE RELATED DEGENERATION; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; ROUS SARCOMA ONCOVIRUS; SCIENTIFIC LITERATURE;

ANTIGENS, SURFACE; APTAMERS, NUCLEOTIDE; CLINICAL TRIALS AS TOPIC; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; PATENTS AS TOPIC; PLATELET-DERIVED GROWTH FACTOR; PROTEINS; SELEX APTAMER TECHNIQUE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 68249092118     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543770903042337     Document Type: Review

References (111)

1. Khan H, Missailidis S. Aptamers in oncology: a diagnostic perspective. Gene Ther Mol Biol 2008;12:111-128
2. Makwana V, Simmons S, Missailidis S. "Aptamers as Anticancer Agents". In: Missailidis S, editor, Anticancer Therapeutics, Wiley & Sons Ltd, UK
3. Janjic N, Gold L, Schmidt P, Vargeese C. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes. US6051698; 1997
4. Zhou B, Wang B. Pegaptanib for the treatment of age-related macular degeneration. Exp Eye Res 2006;83:615-619 (Pubitemid 44183805)
5. Adamis AP, Altaweel M, Bressler NM, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006;113(1):23-28 (Pubitemid 43021723)
6. D'Amico DJ, Masonson HN, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113:992-1001
7. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990;346:818-822 (Pubitemid 20272100)
8. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment - RNA ligands to bacteriophage-T4 DNA-polymerase. Science 1990;249:505-510 (Pubitemid 20248891)
9. Gold L, Tuerk C. Nucleic acid ligands. US5475096; 1995
10. Gold L, Tuerk C. Methods for identifying nucleic acid ligands. US5270163; 1993
11. Gold L, Tuerk C. Nucleic acid ligands. US5670637; 1997
12. Gold L, Tuerk C. Nucleic acid ligands. US5696249; 1997
13. Gold L, Tuerk C. Nucleic acid ligands. US5843653; 1998
14. Gold L, Tuerk C. Nucleic acid ligands. US6110900; 2000
15. Polisky B, Jenison RD, Gold L. High-affinity nucleic acid ligands that discriminate between tehophylline and caffeine. US5580737; 1996
16. Schneider DJ, Vanderslice R, Gold L. Flow cell SELEX. WO1998033941; 1998
17. Pagratis N, Gold L, Shtatland T, Javornik B. Truncation SELEX method. WO2000056930; 2000
18. Biesecker G, Jayasena SD, Gold L, et al. Systematic evolution of ligands by exponential enrichment: blended SELEX. US5683867; 1997
19. Smith JD, Gold L. Transcription-free SELEX. US6387620; 2002
20. Gold L, Rinqquist S. Systematic evolution of ligands by exponential enrichment: solution SELEX. US5567588; 1996
21. Burke D, Tarasow T, Eaton B, Gold L. Systematic evolution of ligands by exponential enrichment: chimeric SELEX. WO199604403; 1996
22. Heiliq JS, Gold L. Systematic evolution of ligands by exponential enrichment: tissue SELEX. US6376474; 2002
23. Gold L, Willis M, Koch T, et al. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution SELEX. US6001577; 1999
24. Sullenger BA, Rusconi CP. RNA aptamers and methods for identifying the same. US7312325; 2007
25. Gold L, Eaton B, Smith D, et al. Systematic evolution of ligands by exponential enrichment: chemi-SELEX. US5763595; 1998
26. Pagratis N, Gold L, Shtatland T, Javornik B. Truncation SELEX method. US6261774; 2001
27. Gold L, Zichi DA, Smith JD. Modified SELEX processes without purified protein. WO2002024954; 2002
28. Bowser M, Mendonsa S. In vitro evaluation of nucleic acid ligands. WO2003102212; 2003
29. West JAA, Satterfield BC. Selection of aptamers based on geometry. 20080182759; 2008
30. Furste JP, Bald R, Erdmann VA. Mirror-symmetrical selection and evolution of nucleic acids. WO1998008856; 1998
31. Kleinjung F, Roehl I, Wientges J. Method and apparatus for designing a nucleic acid having a desired property. EP1386972; 2004
32. Sullenger BA, Layzer JM, Rusconi CP, et al. Focused libraries, functional profiling, laser SELEX and DESELEX. WO2007035532; 2007
33. Pieken W, Tasset D, Janjic N, et al. High affinity nucleic acid ligands containing modified nucleotides. US5660985; 1997
34. Damha M, Peng CG. Aptamers comprising arabinose modified nucleotides. WO2007038869; 2007
35. Dougan AH, Weitz JI. Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. US6780850; 2004
36. Dynan W, Yoo S. Oligomers that bind to KU protein. WO1999033971; 1999
37. Nadeau JG, Ciolkowski ML, Vogler EA. Bi-directional oligonucleotides that bind thrombin. US5668265; 1997
38. Wilson C, Epstein D, Kurz J. Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same. WO2004047742; 2004
39. Li N, Ebright JN, Stovall GM, et al. Technical and biological issues relevant to cell typing with aptamers. J Proteome Res 2009;8:2438-2448
40. Missailidis S, Perkins A, David Santos-Filho S, et al. Aptamer-based radiopharmaceuticals for diagnostic imaging and targeted radiotherapy of epithelial tumors. Braz Arch Biol Technol 2008;51:77-83
41. Janjic N, Gold L, Schmidt P, Vargeese C. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes. US6051698; 2000
42. Available from: www.ClinicalTrials.gov
43. Janjic N, Gold L. High affinity PDGF nucleic acid ligands. US5668264; 1997
44. Pietras K, Ostman A, Heldin C-H, Rubin K. Method for treatment of tumors using nucleic acid ligands to PDGF. US6699843; 2004
45. Pietras K, Ostman A, Sjoquist M. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001;61:2929-2934 (Pubitemid 32691937)
46. Pietras K, Rubin K, Sjoblom T. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002;62:5476-5484
47. Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006;168:2036-2053 (Pubitemid 43825322)
48. Epstein D, Kurz J. Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders. WO2007103549; 2007
49. Sullenger BA, Rusconi CP, Kontos C, White R. RNA aptamers and methods for identifying the same. US20030175703; 2003
50. Janjic N, Gold L, Tasset D. High-affinity ligands of basic fibroblast growth factor and thrombin. WO1995021853; 1995
51. Ruckman J, Gold L, Stephens A, Janjic N. Nucleic acid ligands to integrins. US7094535; 2006
52. Gold L, Pagratis N. High affinity TGFβ nucleic acid ligands and inhibitors. US6124449; 2000
53. Pagratis N, Gold L. High affinity HKGF nucleic acid ligands and inhibitors. US5846713; 1998
54. Ruckman J, Gold L, Stephens A, et al. Nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met and to integrins. WO2001009159; 2001
55. Rabin R, Lochrie M, Janjic N, Gold L. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met. US20030049644; 2003
56. Bates P, Miller DM, Trent JO, Xiaohua X. A method for the treatment of malignant diseases by inhitibing nucleolin. WO2005035579; 2005
57. Trent J, Bates PJ, Miller DM. Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin. US20080318887; US20080318888; US20080318889; US20080318890; 2008
58. Bates PJ, Kahlon JB, Thomas SD, et al. Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J Biol Chem 1999;274:26369-26377 (Pubitemid 129520069)
59. Xu XH, Hamhouvia F, Thomas SD, et al. Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides. J Biol Chem 2001;276:43221-43230 (Pubitemid 37371008)
60. Ireson CR, Kelland LR. Discovery and development of anticancer aptamers. Mol Cancer Ther 2006;5:2957-2962
61. Hicke B, Warren S, Parma D, Gold L. Tenascin-C nucleic acid ligands. US6232071; 2001
62. Friebe M, Hecht M, Dinkelborg L, et al. Aptamers labelled with Gallium-68. WO2008028534; 2008
63. Lupold SE, Lin Y, Hicke BJ, Coffey DS. Nucleic acid ligands to the prostate specific membrane antigen. US6933114; 2005
64. Bruce JI, Missailidis S, Borbas KE, Ferreira CSM. Detection, monitoring and treatment of cancer. WO2004081574; 2004
65. Yokoyama S, Hirao I, Sakamoto K. Nucleic acid capable of binding specifically to Ras target protein. US6995249; 2006
66. Dzau VJ, Gibbons GH, Morishita R. Therapeutic use of CIS-element decoys in vivo. US6774118; 2004
67. Dua P, Kim S, Lee D-K. Patents on SELEX and therapeutic aptamers. Recent Patents DNA Gene Sequences 2008;2:172-186
68. Jayasena SD, Gold L. Nucleic acid ligand inhibitors of human neutrophil elastase. US5734034; 1998
69. Charlton J, Kirschenheuter GP, Smith D. Highly potent irreversible inhibitors of neutrophil elastase generated by selection from a randomized DNA-valine phosphonate library. Biochemistry 1997;36:3018-3026 (Pubitemid 27138587)
70. Smith D, Kirschenheuter GP, Charlton J, et al. In vitro selection of RNA-based irreversible inhibitors of human neutrophil elastase. Chem Biol 1995;2:741-750
71. Charlton J, Sennello J, Smith D. In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase. Chem Biol 1997;4:809-816
72. Gold L, Parma D, Janjic N, Lochrie M. High-affinity oligonucleotide ligands to secretory phospholipase A2(SPLA2). WO1996027604; 1996
73. Parma DH, Hicke B, Bridonneau P, Gold L. High affinity nucleic acid ligands to lectins. US5780228; 1998
74. Purschke W, Jarosch F, Eulberg D, et al. MCP-I binding nucleic acids. WO2007093409; 2007
75. Purschke W, Jarosch F, Eulberg D, et al. SDF-I binding nucleic acids. WO2008009437; 2008
76. Gorenstein DG, Aronson J, Luxon B, Herzog N. Thio-modified aptamer synthetic methods and compositions. WO2000024404; 2000
77. Diener JL, Epstein D, Ferguson A, et al. Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics. WO2007035922; 2007
78. Lochrie MA, Gold L. High affinity HIV-1 gag nucleic acid ligands. US5726017; 1998
79. Gold L, Tuerk C. Nucleic acid ligands to HIV-RT and HIV-1 rev. US5496938; 1996
80. Schneider DJ, Gold L, Feigon J. Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase. US5503978; 1996
81. Allen PN, Gold L. High affinity HIV nucleocapsid nucleic acid ligands. US5654151; 1997
82. Allen P, Gold L. High affinity nucleic acid ligands to HIV integrase. US5587468; 1996
83. Gold L, Tuerk C. Ligands of HIV-1 tat protein. US5527894; 1996
84. Wilson C, Epstein D, Diener JL. Prophylactic and therapeutic HIV aptamers. WO2004026260; 2004
85. Nishikawa S, Sekiya S, Penmeccha K. RNA molecule forming heterodimer and targeting NS3 protease of hepatitis C virus. JP2005151890; 2005
86. Lee S-W, Shin K-S, Lim J-H, et al. Nuclease resistant RNA aptamer inhibiting replication of hepatitis C virus replicon. WO2008066231; 2008
87. Blatt L, Macejak D, Mcswiggen J, et al. Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication. WO2002081494; 2002
88. Benseler F, Cole JL, Olsen DB, Kuo LC. Capped synthetic RNA, analogs, and aptamers. US5861501; 1999
89. Wang J-F, Pan W. Compositions and methods of developing oligonucleotides and oligonucleotide analogs having antiviral activity. WO1997020072; 1997
90. Vivekananda J, Kiel JL. Methods and compositions for aptamers against anthrax. US6569630; 2003
91. Morrissey D, Haeberli P. Nulceic acid mediated inhibition of enterococcus infection and cytolysin toxin activity. WO2003106476; 2003
92. Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006;103:6315-6320
93. Farokhzad OC, Jon S, Khademhosseini A, et al. Nanopartide-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 2004;64:7668-7672 (Pubitemid 39446893)
94. Chu TC, Twu KY, Ellington AD, Levy M. Aptamer mediated siRNA delivery. Nucleic Acids Res 2006;34:e73
95. Chu TC, Marks JW 3rd, Lavery LA, et al. Aptamer: toxin conjugates that specifically target prostate tumor cells. Cancer Res 2006;66:5989-5992
96. Chu TC, Shieh F, Lavery LA, et al. Labeling tumor cells with fluorescent nanocrystal-aptamer bioconjugates. Biosens Bioelectron 2006;21:1859-1866
97. Velasco-Garcia MN, Missailidis S. New trends in aptamer-based electrochemical biosensors. Gene Ther Mol Biol 2009;13:1-10
98. Gariepy J, Ferreira CSM, Missailidis S. Aptamers directed to recombinant MUC1. WO2007129114; 2007
99. Diener JL, Lagasse DHA, Benedict C. Aptamers t von Willebrand factor and their use as thrombotic disease therapeutics. US20060183702; 2006
100. Avci-Adali M, Paul A, Ziemer G, Wendel HP. New strategies for in vivo tissue engineering by mimicry of homing factors for self-endothelialisation of blood contacting materials. Biomaterials 2008;29:3936-3945
101. Nieuwlandt DT, Gold L, Wecker M. High-affinity oligonucleotide ligands to the tachykinin substance P. US5648214; 1997
102. Bracht F, Schror K. Cathepsin G-inhibiting aptamers. US5780449; 1998
103. Stephens A, Gold L, Speck U. Nucleic acid ligands of tissue target. US6127119; 2000
104. Korman AJ, Gold L. Nucleic acid ligands to CD40 ligand. US6171795; 2001
105. Jayasena S, Gold L. Nucleic acid ligand inhibitors to DNA polymerases. US6183967; 2001
106. Yokoyama S, Hirao I, Sakamoto K. Nucleic acid capable of binding specifically to Ras target protein. WO2000009684; 2000
107. Lin A, Marsh HC Jr, Stewart SE. Aptamers for complement protein C3b. WO1997042317; 1997
108. Epstein D, Wilson C, Diener JL. Regulated aptamer therapeutics. WO2004011680; 2004
109. Janjic N, Gold L, Schmidt P. Vascular endothelial growth factor (VEGF) nucleic acid ligand. US5859228; 1999
110. Rusconi C. Improved modulators of coagulation factors. WO2005106042; 2005
111. Diener JL, Lagasse DHA. Aptamers to von willebrand factor and their use as thrombotic disease therapeutics. WO2006033854; 2006